Holmes was convicted of harming patients.
The January 2022 verdict convicted her on investor-related counts and acquitted her on patient-related wire-fraud counts. Balwani was convicted on patient-related counts.
What remained after 2022: Ninth Circuit appeals, restitution, the difference between CMS findings and Holmes’s patient counts, and persistent myths.
Darker cells mean a higher score for this topic on that metric.
LessMore
Last reviewed Sources & creditsMedia creditsMethodology
The company claimed its devices could run a broad menu of clinical laboratory tests from a finger-stick or other small sample, faster and cheaper than a conventional venous draw sent to a central lab.
The Wall Street Journal published John Carreyrou’s first major investigation on 15 October 2015. CMS sanctions, SEC charges (2018), and criminal trials followed.
On 3 January 2022 a Northern District of California jury convicted her of conspiracy to commit wire fraud and three counts of wire fraud involving investors. She was acquitted on several other counts, including patient-related wire-fraud counts.
Judge Edward J. Davila sentenced Holmes on 18 November 2022 to 135 months (11 years and 3 months) in federal prison, plus supervised release and restitution to be determined in the judgment papers.
Ramesh Balwani was convicted in July 2022 on all twelve counts he faced, including investor and patient-related fraud, and was sentenced in December 2022 to 155 months.
CMS findings and trial evidence included inaccurate or unreliable results from the Newark lab. Holmes was not convicted on the patient-fraud counts; Balwani was. Civil and regulatory files address laboratory quality separately from those verdicts.
The trial court finished in 2022. Appeals, surrender dates, and restitution calculations are the administrative aftermath.
The most common error in English-language recaps is treating Holmes’s verdict as a clean sweep on patients.
Holmes was convicted of harming patients.
The January 2022 verdict convicted her on investor-related counts and acquitted her on patient-related wire-fraud counts. Balwani was convicted on patient-related counts.
The Journal invented the problems.
CMS inspections and two juries independently found serious false statements and laboratory failures after the 2015 articles.
No blood tests were ever run.
Tests were offered and run, including on third-party machines. The fraud theory was about what the company’s own technology and validations could do, not about a total absence of any assay.
A $9 billion public company vanished.
Theranos was private. The $9 billion figure was a 2014 fundraising valuation reported in the press, not an exchange capitalization.
English-language finance and tech desks still treat Carreyrou’s series as the model for a stealth-biotech takedown — a prestige that shapes how later device startups are covered.
U.S. and U.K. features leaned on costume and voice. Serious legal coverage had to keep pulling readers back to the verdict form.
Coverage of famous limited partners sometimes outran the CMS file. The encyclopedia keeps the laboratory and the jury ahead of the guest list.
The aftermath is a split verdict that popular culture keeps trying to make simple, and a laboratory file that was already grim before the jury sat.
Public-record encyclopedia. Not legal advice. Not a how-to. Graphic detail is withheld. Wars belong in a separate atlas.